CYP2C19
CYP2C19 (cytochrome P450 family 2 subfamily C member 19, also known as P450IIC19, CPCJ and CYP2C) is an endoplasmic reticulum monooxygenase that metabolises polyunsaturated fatty acids and many therapeutic drugs. It was previously named mephenytoin 4-hydroxylase. Browse Assay Genie's current range of CYP2C19 research reagents below, or read on for the biology behind the target.
CYP2C19 is a cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA). Mechanistically, it uses molecular oxygen, inserting one oxygen atom into the substrate and reducing the second to water, with two electrons supplied by NADPH through cytochrome P450 reductase (NADPH--hemoprotein reductase). It catalyses the hydroxylation of carbon-hydrogen bonds, hydroxylates PUFA specifically at the omega-1 position, and catalyses the epoxidation of PUFA double bonds.
The enzyme also metabolises plant monoterpenes such as limonene, oxygenating (R)- and (S)-limonene to carveol and perillyl alcohol. It is responsible for the metabolism of a number of therapeutic agents, including the anticonvulsant S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine, and it hydroxylates fenbendazole at the 4' position. The protein localises to the endoplasmic reticulum and microsome membranes.
The CYP2C19 gene belongs to the cytochrome P450 family 2 gene group and lies within a cluster of cytochrome P450 genes on chromosome 10q. Polymorphism in this gene is associated with variable ability to metabolise mephenytoin, described as the poor metabolizer and extensive metabolizer phenotypes. The earlier gene name, cytochrome P450 subfamily IIC (mephenytoin 4-hydroxylase) polypeptide 19, reflects this pharmacological history. Related enzymes in the same subfamily include CYP2C8, CYP2C9 and CYP2C18.
CYP2C19 metabolises drugs including S-mephenytoin, omeprazole, diazepam, propranolol, citalopram and imipramine, making it a central enzyme in xenobiotic metabolism research.
Polymorphism in the CYP2C19 gene is associated with poor and extensive metaboliser phenotypes for mephenytoin, linking genotype to variable drug handling.
The enzyme hydroxylates polyunsaturated fatty acids at the omega-1 position and epoxidises their double bonds, placing it in lipid oxidation pathways.
As an NADPH- and cytochrome P450 reductase-dependent monooxygenase, CYP2C19 is a model for studying oxygen insertion and substrate hydroxylation.
CYP2C19 is a cytochrome P450 monooxygenase that hydroxylates and epoxidises polyunsaturated fatty acids, oxygenates limonene, and metabolises drugs such as S-mephenytoin, omeprazole, diazepam and citalopram. It uses NADPH-derived electrons supplied by cytochrome P450 reductase and molecular oxygen.
CYP2C19 is also called P450IIC19, CPCJ and CYP2C, and UniProt names it cytochrome P450 2C19. Earlier HGNC names include cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19. Its EC number is 1.14.14.1.
Polymorphism within the CYP2C19 gene is associated with variable ability to metabolise mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. Mouse and rat orthologues are not specified in the source data, so check the datasheet of any product for its validated reactivity.
Other cytochrome P450 family 2 members and drug-metabolising enzymes with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P33261; product specifications from Assay Genie datasheets.